FINWIRES · TerminalLIVE
FINWIRES

China's Onshore ESG Bond Issuance Declines 21% in Q1, Fitch Says

By

China's onshore ESG bond issuance dropped 21% year on year in the first quarter, a reversal from a 70% rise in 2025, Sustainable Fitch said in a recent release.

Offshore issuance continued to be muted, with sovereign activity driving early second-quarter trends, the ESG data provider said.

ESG-labeled panda bond issuance doubled in the first quarter, due to competitive renminbi funding rates and enhanced panda bond systems, Sustainable Fitch said.

However, ESG-labeled bonds still have a small share in total panda bond issuance, driven by sovereign and supranational issuers and with limited corporate participation, the data provider said.

Related Articles

Asia

GSH to Raise SG$5 Million Via ADDX Issuance

GSH (SGX:BDX) is looking to raise SG$5 million through the issuance of bonds on the ADDX Exchange, according to a Thursday filing with the Singapore Exchange.The facility comprises 46th, 47th and 48th issues under the CP facility program, carrying interest rates of 3.80%, 4.15% and 4.45% respectively.

$SGX:BDX
Asia

Xin Hee to Lease Factory Building to AI Company in Xiamen, China

Xin Hee (SHE:003016) leased out a factory building to an artificial intelligence company in Xiamen, China, according to a Thursday filing with the Shenzhen bourse.The lease to Xiamen Qiannianjun Artificial Intelligence Technology, worth a total of 6.4 million yuan, is valid from June 1, 2026, to Nov. 23, 2030.

$SHE:003016
Asia

Caliway Completes FDA IND Filing for Phase 3b CBL-514 Trial of Abdominal Fat Reduction Drug

Caliway Biopharmaceuticals (TPE:6919) completed its U.S. FDA IND submission for a Phase 3b long-term follow-up study of its abdominal subcutaneous fat reduction drug, according to a Wednesday Taiwan Exchange filing.The study, dubbed CBL-0303, is designed to evaluate long-term safety and maintenance of efficacy of the drug called CBL-514, before the trail.It is expected to enroll around 300 participants in the United States. The protocol also includes an optional re-treatment phase for eligible patients, the filing said.

$TPE:6919